Aripiprazole, olanzapine and haloperidol pamoate salts
The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures. The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.
1 . A pamoate salt of haloperidol.
2 . The pamoate salt of claim 1 , wherein the ratio of haloperidol to pamoate is 1:1 or 2:1.
3 . The pamoate salt of claim 1 , wherein the salt is a needle.
4 . The pamoate salt of claim 1 , wherein the salt is crystalline.
5 . A pamoate salt of aripiprazole.
6 . The pamoate salt of claim 4 , wherein the ratio of aripiprazole to pamoate is 1:1 or 2:1.
7 . The pamoate salt of claim 5 , wherein the salt is crystalline.
8 . A method of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of an active agent selected from the group consisting of haloperidol and aripiprazole.
9 . The method of claim 8 , wherein the composition is administered by injection.
10 . The method of claim 8 , wherein the composition is administered intramuscularly or subcutaneously.
11 . The method of claim 8 , wherein the composition releases an effective amount of the active agent over a period of at least about 24 hours.
12 . The method of claim 8 , wherein the composition releases an effective amount of the active agent over a period of at least about 48 hours.
13 . The method of claim 8 , wherein said composition consists essentially of the pamoate salt and a viscous aqueous carrier.
14 . The method of claim 8 , wherein said composition is an extended release formulation comprising a biodegradable polymer and the pamoate salt.
15 . The method of claim 14 , wherein the extended release formulation comprises a polylactide and the pamoate salt.
16 . The method of claim 14 , wherein the extended release formulation comprises a polylactide-co-glycolide and the pamoate salt.